Toll Free: 1-888-928-9744

Perennial Allergic Rhinitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Perennial Allergic Rhinitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Perennial Allergic Rhinitis - Pipeline Review, H1 2015', provides an overview of the Perennial Allergic Rhinitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Perennial Allergic Rhinitis Overview 6
Therapeutics Development 7
Pipeline Products for Perennial Allergic Rhinitis - Overview 7
Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis 8
Perennial Allergic Rhinitis - Therapeutics under Development by Companies 9
Perennial Allergic Rhinitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Perennial Allergic Rhinitis - Products under Development by Companies 12
Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development 13
Adamis Pharmaceuticals Corporation 13
FAES Farma SA 14
GenMont Biotech Inc. 15
GlaxoSmithKline plc 16
Hanmi Pharmaceuticals, Co. Ltd. 17
Merck & Co., Inc. 18
Pfizer Inc. 19
Shionogi & Co., Ltd. 20
VentiRx Pharmaceuticals, Inc. 21
Perennial Allergic Rhinitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
APC-3000 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
bilastine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
desloratadine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
fluticasone furoate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GMNL-32 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PF-06444752 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PF-06444753 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
S-555739 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VTX-1463 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Perennial Allergic Rhinitis - Recent Pipeline Updates 44
Perennial Allergic Rhinitis - Dormant Projects 47
Perennial Allergic Rhinitis - Discontinued Products 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50
List of Tables
Number of Products under Development for Perennial Allergic Rhinitis, H1 2015 7
Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Perennial Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 13
Perennial Allergic Rhinitis - Pipeline by FAES Farma SA, H1 2015 14
Perennial Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2015 15
Perennial Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H1 2015 16
Perennial Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 17
Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2015 18
Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2015 19
Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2015 20
Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Assessment by Combination Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Perennial Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2015 44
Perennial Allergic Rhinitis - Dormant Projects, H1 2015 47
Perennial Allergic Rhinitis - Discontinued Products, H1 2015 48 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify